19 December 2022 - director dealing
The AIM-listed specialist infection control company has announced that non-executive director John Langlands has bought 500,000 shares in the company at a price of 2.21p. This is encouraging news following the recent announcement of the results and the company recently presented on the Investor Meet platform as a further indication that they are looking to raise their profile with investors. We therefore continue to rate the shares as a SPECULATIVE BUY
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
